Navigation Links
Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance
Date:1/28/2010

($269 net of tax ($0.01 per diluted share)) of costs related to litigation resulting from our internal stock option investigation.

(D) The quarter ended December 27, 2008 includes a $19,286 ($0.80 per diluted share) non-cash charge for the impairment of all of the goodwill of our Commercial Lasers and Components segment.

(E) Changes in deferred compensation plan liabilities are included in cost of sales and operating expenses while gains and losses on deferred compensation plan assets are included in other income (expense) net.  Deferred compensation expense (benefit) included in operating results is summarized below:

    
    
    
    
    Deferred compensation expense
     (benefit)                                 Three Months Ended
                                               ------------------
                                     January 2,    October 3,    December 27,
                                        2010          2009           2008
                                        ----          ----           ----
    Cost of sales                        $32           $43          $(174)
    Research & development               132           182           (988)
    Selling, general &
     administrative                    1,114         1,476         (5,784)
                                       -----         -----         ------
    Impact on income (loss)
     from operations                  $1,278        $1,701        $(6,946)
                                      ------        ------        -------
    
    

For the quarters ended January 2, 2010, October 3, 2009 and December 27, 2008, the impact on other income (expense) net from gains or losses on deferred compensation plan assets was income of '/>"/>

SOURCE Coherent, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Coherent, Inc. to Webcast Third Fiscal Quarter 2008 Results
2. Coherent, Inc. Announces Termination of SEC Informal Inquiry
3. Coherent, Inc. to Webcast Fourth Fiscal Quarter 2007 Results
4. Coherent, Inc. Receives Expected Letter from NASDAQ
5. Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. Medicago reports positive Phase I results for its avian flu pandemic vaccine
8. Neogen Reports 18% Increase in Net Income
9. EntreMed Reports Receipt of Third Quarter Royalty Payment
10. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
11. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Adjusted Earnings and Backlog Increase to Record Highs, ... ), a diversified medical technologies company specializing in,diagnostics, imaging ... of women, today announced its results for the,quarter ended ... include:, -- Record revenues of $371.4 million. ...
... Product Candidate Trop-2 Signal ... Transduction Antibody -, ... full-,service biopharmaceutical development and protein production company, today,announced that it ... Inc., a biotechnology company focused on discovering,and developing the next ...
... Jan. 31 /PRNewswire-FirstCall/ - ARIUS Research Inc., ... the next wave of,antibody therapeutics, today announced ... manufacturing agreement for its Trop-2 Signal Transduction,Antibody ... and protein production company located in Princeton, ...
Cached Biology Technology:Hologic Announces First Quarter Fiscal 2008 Operating Results 2Hologic Announces First Quarter Fiscal 2008 Operating Results 3Hologic Announces First Quarter Fiscal 2008 Operating Results 4Hologic Announces First Quarter Fiscal 2008 Operating Results 5Hologic Announces First Quarter Fiscal 2008 Operating Results 6Hologic Announces First Quarter Fiscal 2008 Operating Results 7Hologic Announces First Quarter Fiscal 2008 Operating Results 8Hologic Announces First Quarter Fiscal 2008 Operating Results 9Hologic Announces First Quarter Fiscal 2008 Operating Results 10Hologic Announces First Quarter Fiscal 2008 Operating Results 11Hologic Announces First Quarter Fiscal 2008 Operating Results 12Hologic Announces First Quarter Fiscal 2008 Operating Results 13Hologic Announces First Quarter Fiscal 2008 Operating Results 14Hologic Announces First Quarter Fiscal 2008 Operating Results 15Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 3ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody 2ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody 3ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody 4
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season ... industry as Acuity Market Intelligence reports that the ... be open. Acuity forecasts that intensifying demand for ... incorporate biometrics will drive a global market of ... devices by 2020.   According to ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ... its team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... conservation successes in the face of rapid environmental change ... adapt to local climate. To improve scientists, understanding ... 2011 issue of Science helps define the ... The National Science Foundation partly funded the study, which ...
... and technologies from more than 850 scientific, technical and ... 95th Annual Meeting, Frontiers in Optics (FiO) 2011, being held ... Sainte Claire hotels in San Jose, Calif. Held in conjunction ... Physical Society (APS) Division of Laser Science (DLS), the meeting ...
... The scope and intensity of mercury pollution in ... reported, but additional mercury controls should bring needed improvement, ... the subject. Despite general declines in mercury levels ... decades, mercury concentrations still exceed human and ecological risk ...
Cached Biology News:Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 2Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 3Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 4Mercury pollution in the Great Lakes region -- nearly forgotten, but not gone 2Mercury pollution in the Great Lakes region -- nearly forgotten, but not gone 3
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Biology Products: